GSK plc: Jemperli's Head-To-Head Keytruda Win Stops Price Rot
GSK stock has endured a torrid year-to-date - down 21% in a sector that is performing much better than the S&P. Click here to read my analysis of GSK stock.
Source: seekingalpha.com
Page 14 - Objective Response Rate News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Objective Response Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Objective Response Rate Today - Breaking & Trending Today
OncoSec Announces Pipeline Prioritization and Workforce Reduction
/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...
Source: prnewswire.com
OncoSec Announces Pipeline Prioritization and Workforce Reduction
/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...
Source: prnewswire.com
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer
Source: finanznachrichten.de
Adaptimmune Therapeutics PLC: Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development planned
Source: finanznachrichten.de